Sosei’s Cancer Breakthrough Pain Drug Moves Step Closer To Market
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Sosei has started Phase III studies in Europe for its novel fentanyl sublingual spray AD 923, an opiod analgesic used for the treatment of cancer breakthrough pain, the Tokyo-based biopharmaceutical company announced Feb. 12